Clinical Trial Update: AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial sponsored by the University of Florida evaluating an artificial intelligence–based drug-dosing approach for hepatocellular carcinoma. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: University of Florida | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING